Eton Pharmaceuticals, Inc. (ETON) stock
ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30538% above fair value
$60.85−0.51 (-0.83%)
Close on Nov 20, 2026Market cap $1.74BP/E 156.0Yield –
Eton Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Eton Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $14.73M, up 20.5% year over year. For fiscal 2025 it was $10.19M, up 980.7% from the year before. The highest annual figure on record is $10.19M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.19M | +980.7% |
| FY2024 | Dec 31, 2024 | $943.00K | -86.2% |
| FY2023 | Dec 31, 2023 | $6.82M | +42.5% |
| FY2022 | Dec 31, 2022 | $4.78M | – |
| FY2021 | Dec 31, 2021 | -$4.73M | – |
| FY2020 | Dec 31, 2020 | -$22.40M | – |
| FY2019 | Dec 31, 2019 | -$19.12M | – |
| FY2018 | Dec 31, 2018 | -$8.38M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.26M | -8.8% |
| Q1 FY2026 | Mar 31, 2026 | $7.33M | +250.7% |
| Q4 FY2025 | Dec 31, 2025 | -$11.60M | – |
| Q3 FY2025 | Sep 30, 2025 | $11.74M | +297.8% |
| Q2 FY2025 | Jun 30, 2025 | $7.96M | +534.2% |
| Q1 FY2025 | Mar 31, 2025 | $2.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$777.00K | -300.8% |
| Q3 FY2024 | Sep 30, 2024 | $2.95M | +238.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.26M | -82.3% |
| Q1 FY2024 | Mar 31, 2024 | -$2.49M | – |
| Q4 FY2023 | Dec 31, 2023 | $387.00K | -86.3% |
| Q3 FY2023 | Sep 30, 2023 | $873.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $7.10M | +189.9% |
| Q1 FY2023 | Mar 31, 2023 | -$1.55M | -228.1% |
| Q4 FY2022 | Dec 31, 2022 | $2.83M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.70M | – |
| Q2 FY2022 | Jun 30, 2022 | $2.45M | – |
| Q1 FY2022 | Mar 31, 2022 | $1.21M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.12M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.95M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.23M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.85M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.22M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.88M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.25M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.84M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.16M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.83M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.34M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.27M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.94M | – |
See a number that looks wrong?